TP53 and acute lymphoblastic leukemia: Although alterations of TP53 are infrequent at disease presentation (< 15%) in ALL, they are significantly enriched at relapse (up to 30%) and in the high-risk low hypodiploid ALL subgroup (> 90%) [6–10].